Controversy sparks over CJ's trademark Simvasta
Published: 2004-10-21 06:58:00
Updated: 2004-10-21 06:58:00
The ongoing discord between the Korean Intellectual Property Office and Hanmi Pharm over the CJ Corporation's trademark Simvasta (simvastatin), a lipid lowering agent, has intensified in the wake of the KIPO's recent grant on that trademark.
In addressing concerns about possible restriction to...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
